Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Neurophysiological Biomarkers of CAD-9303 Oral Treatment in Subjects With Schizophrenia and Normal Healthy Volunteers

NCT04306146 is registered in ClinicalTrials.gov with Cadent Therapeutics as lead sponsor.

NCT NCT04306146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04306146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Neurophysiological Biomarkers of CAD-9303 Oral Treatment in Subjects With Schizophrenia and Normal Healthy Volunteers
Lead sponsor
Cadent Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2020
Completion date
November 24, 2021
Enrollment
103 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia